Myrbetriq
Myrbetriq is a bladder medication containing Mirabegron, available as 50mg tablets.
- Category
- Bladder
- Active ingredient
- Mirabegron
- Route
- Oral use
- Form
- Prolonged-release tablet
- Strengths
- 50mg
Prescription rules on Myrbetriq vary by country.
Details
- Conditions
- Overactive bladder
- Alternative Name
- Betmiga
- Therapeutic Class
- Beta-3 Adrenoceptor Agonist
- Pharmacological Class
- Beta-3 Adrenoceptor Agonist
- Minor Side Effects
- tachycardia, urinary tract infection, nausea, headache
- Moderate Side Effects
- hypertension, dyspepsia, constipation
- Dosage Forms
- Prolonged-release tablet
- Administration Route
- Oral use
- Prescription Status
- Available without prescription
- Manufacturer
- Astellas
- Onset Time
- 1–2 weeks
- Duration
- 24 hours
- Storage Instructions
- Store at room temperature, away from excessive heat and moisture.
- Drug Interactions
- metoprolol, digoxin, flecainide, propafenone
- Age Restrictions
- Not recommended for children or adolescents.